Zugo-cel is named as an intervention in 3 current clinical trials in our USA, Germany, Spain and Australia registers. 3 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is CRISPR Therapeutics AG (2). The most-studied condition is B-cell Lymphoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742 · ClinicalTrials.gov ↗ · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
|
Phase 1/2 | Recruiting | CRISPR Therapeutics AG | USA, Australia |
|
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT07549698 · ClinicalTrials.gov ↗ · Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
|
Phase 1/2 | Recruiting | CRISPR Therapeutics AG | USA, Germany, Spain |
|
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542 · ClinicalTrials.gov ↗ · SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis
|
Phase 1 | Recruiting | CRISPR Therapeutics | USA, Germany, Spain |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| CRISPR Therapeutics AG | 2 |
| CRISPR Therapeutics | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 3 |
| Clinical trials in Germany | 2 | 2 |
| Clinical trials in Spain | 2 | 2 |
| Clinical trials in Australia | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, Germany, Spain and Australia registers name Zugo-cel (also registered as CTX112) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 3 with sites in USA, 2 with sites in Germany, 2 with sites in Spain and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
CRISPR Therapeutics AG (2) and CRISPR Therapeutics (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zugo-cel works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zugo-cel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zugo-cel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.